Telix (ASX:TLX) has announced that it has been jointly awarded a $4.8 million Australian Research Council grant to establish a new Industrial Transformation Research Program Hub as part of a consortium of applicants led by The University of Queensland.
-
Latest News Telix and UQ-led consortium awarded Australian Research Council grant August 9, 2022
-
Latest News Dimerix announces new patent family for DMX-700 August 9, 2022Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.
-
Latest News Pfizer raises offer for Australian digital health company August 4, 2022Pfizer has significantly raised its offer for Australian digital health company ResApp Health (ASX:RAP) to a price that reflects the recent findings of an independent report.
-
AusBiotech AusBiotech 2022 programme features top industry experts August 4, 2022AusBiotech is delighted to reveal a ‘sneak peek’ into the AusBiotech 2022 programme, which features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.
-
Latest News Medical Developments International announces fully underwritten capital raise August 4, 2022Medical Developments International (ASX:MVP) has announced a fully underwritten capital raising of $30 million.
-
Latest News Radiopharm Theranostics announces new agreements with Lantheus and NanoMab August 4, 2022Radiopharm Theranostics (ASX:RAD) has announced a collaboration agreement with Lantheus.
-
Latest News Osteopore secures US distribution agreement for government facilities August 4, 2022Osteopore (ASX:OSX) has announced that US-based distributor Bioplate has secured a non-exclusive agreement with MellingMedical to promote and sell its products within healthcare facilities owned or operated by the US government.
-
Latest News Immutep reports new data from phase 2 TACTI-002 trial August 2, 2022Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials.
-
AusBiotech Australia’s Cell and Gene Catalyst moves ahead August 2, 2022Australia’s Cell and Gene Catalyst will move ahead, establishing its inaugural Steering Group and opening recruitment, formally signalling the important next step in advancing cell and gene accessibility in Australia.
-
Latest News Lumos Diagnostics announces plan to close US facility August 2, 2022Lumos Diagnostics (ASX:LDX) has announced its intention to close its facility in the US-state of Florida.
-
Latest News New study published demonstrating the utility of PromarkerD test August 2, 2022Proteomics International Laboratories (ASX:PIQ) has announced that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease has been published in the journal PLOS ONE.
-
Latest News Recruitment open for new study of lung disease August 2, 2022Australian researchers are seeking volunteers aged 40 and over living with severe emphysema for a world-first study of a novel two-stage procedure to treat the lung disease.
-
Latest News Genetic Signatures completes recruitment in pivotal clinical trial July 28, 2022Molecular diagnostics company Genetic Signatures (ASX:GSS) has completed recruitment for the clinical trial of its 3base EasyScreen Enteric Protozoan Diagnostic Kit in the US.
-
AusBiotech Nominations open to recognise sector leaders July 28, 2022Nominations for the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are now open.
-
Latest News MTPConnect launches next funding opportunity for medical device companies July 28, 2022The Clinical Translation and Commercialisation Medtech Program will open its second round in September 2022 seeking applications from small to medium-sized enterprises.
-
Latest News Volpara Health announces outcomes of strategic review July 28, 2022Volpara Health Technologies (ASX:VHT) has announced the completion of the strategic review undertaken by CEO Teri Thomas and the executive management team.
-
Latest News Immuron provides update on FDA review of IND application July 28, 2022Immuron (ASX:IMC) has announced that the US Naval Medical Research Center has received feedback from the US FDA following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.
New Stories
-
Neuren commences enrolment new Phase 2 trials of NNZ-2591
August 9, 2022 - - AusBiotech -
Life sciences directory to connect the industry
August 9, 2022 - - AusBiotech -
Telix and UQ-led consortium awarded Australian Research Council grant
August 9, 2022 - - Latest News -
Neuren commences enrolment new Phase 2 trials of NNZ-2591
August 9, 2022 - - Latest News -
Dimerix announces new patent family for DMX-700
August 9, 2022 - - Latest News -
Lumos withdraws from participation in Victorian manufacturing proposal
August 8, 2022 - - Latest News -
Osteopore secures US distribution agreement for government facilities
August 4, 2022 - - Latest News